913566-75-3

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 635-93-8 5-chlorosalicyclaldehyde 
• 478313-95-0 N'-[1-(5-Chloro-2-hydroxy-phenyl)-meth-(E)-ylidene]-hydrazinecarboxylic acid tert-butyl ester 

Downstream Products

• 851205-62-4 1-(5-chloro-2-hydroxybenzyl)-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1354060-39-1 1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1354060-40-4 {1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-methanol 
• 1354060-41-5 1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazole-3-carbaldehyde 
• 1354060-42-6 (E)-3-{1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-acrylic acid methyl ester 
• 1354060-43-7 3-{1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-propionic acid methyl ester 
• 1354060-44-8 3-{1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-propionic acid 
• 1354060-45-9 3-{1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-propionyl fluoride 
• 1354060-38-0 N-(3-{1-[5-chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-propionyl)-C,C,C-trifluoromethanesulfonamide 
• 1444317-34-3 N-{1-[5-chloro-2-(4-methoxybenzyloxy)benzyl]-5-methyl-1H-pyrazole-3-carbonyl}benzenesulfonamide 
• 1444317-47-8 1-[5-chloro-2-(4-methoxybenzyloxy)benzyl]-5-methyl-1H-pyrazole-3-carbonyl fluoride 
• 1444317-46-7 1-[5-chloro-2-(4-methoxybenzyloxy)benzyl]-5-methyl-1H-pyrazole-3-carboxylic acid 
• 1444317-31-0 1-(5-chloro-2-cyclopentylmethoxybenzyl)-5-methyl-1H-pyrazole-3-carboxylic acid 
• 1444317-40-1 1-(5-chloro-2-cyclopentylmethoxybenzyl)-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

The present invention provides a compound, that is wherein Y, W, Z, R1, R2, R4, R5 and R6 are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.

COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substit

PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R1 ,R2a, R2b, R10, R11 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Identification of novel pyrazole acid antagonists for the EP1 receptor

The discovery, synthesis and structure-activity relationship (SAR) of a novel series of EP1 receptor antagonists is described. Pyrazole acid 4, identified from a chemical array, had desirable physicochemical properties, an excellent in vitro microsomal inhibition and cytochrome P450 (CYP450) profile and good exposure levels in blood. This compound had an ED50 of 1.3 mg/kg in a rat pain model. A range of more potent analogues in the in vitro assay was identified using efficient array chemistry. These EP1 antagonists have potential as agents in the treatment of PGE2 mediated pain.